Krueger GG - Search Results

1

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG. Lebwohl M, et al. Among authors: krueger gg. Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x. Epub 2009 Nov 9. Br J Dermatol. 2010. PMID: 19903183 Clinical Trial.

2

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators. Langley RG, et al. Among authors: krueger gg. Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22. Br J Dermatol. 2015. PMID: 25307931 Free article. Clinical Trial.

3

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Among authors: krueger gg. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.

4

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.

Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. Gordon KB, et al. Among authors: krueger gg. J Invest Dermatol. 2012 Feb;132(2):304-14. doi: 10.1038/jid.2011.304. Epub 2011 Oct 20. J Invest Dermatol. 2012. PMID: 22011907 Free article. Clinical Trial.

5

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score.

Papp KA, Lebwohl MG, Kircik LH, Pariser DM, Strober B, Krueger GG, Berk DR, Navale L, Higham RC. Papp KA, et al. Among authors: krueger gg. Dermatol Ther (Heidelb). 2021 Aug;11(4):1079-1083. doi: 10.1007/s13555-021-00572-2. Epub 2021 Jul 8. Dermatol Ther (Heidelb). 2021. PMID: 34236691 Free PMC article.

6

A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.

Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. Lebwohl M, et al. Among authors: krueger gg. Int J Dermatol. 2002 May;41(5):269-74. doi: 10.1046/j.1365-4362.2002.01431.x. Int J Dermatol. 2002. PMID: 12100701 Clinical Trial.

7

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.

Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G. Lebwohl M, et al. J Am Acad Dermatol. 1998 Sep;39(3):464-75. doi: 10.1016/s0190-9622(98)70325-1. J Am Acad Dermatol. 1998. PMID: 9738783 Review.

8

Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.

van de Kerkhof P, Griffiths CE, Christophers E, Lebwohl M, Krueger GG. van de Kerkhof P, et al. Among authors: krueger gg. Dermatology. 2005;211(3):256-63. doi: 10.1159/000087020. Dermatology. 2005. PMID: 16205071 Clinical Trial.

9

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group. Krueger GG, et al. N Engl J Med. 2007 Feb 8;356(6):580-92. doi: 10.1056/NEJMoa062382. N Engl J Med. 2007. PMID: 17287478 Free article. Clinical Trial.

10

Consensus guidelines for the management of plaque psoriasis.

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board. Hsu S, et al. Among authors: krueger gg. Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410. Arch Dermatol. 2012. PMID: 22250239

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

258 results

Search Page